FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eric Van Cutsem

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Hannah van Malenstein; Jeroen Dekervel; Frederik Nevens; Eric Van Cutsem; Chris Verslype; Petra Windmolders; Jos van Pelt
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Sofie Van Binnebeek; Eric Van Cutsem; Bert Vanbilloen; Alfons Verbruggen; Chris Verslype; Karin Haustermans; Luc Mortelmans; Felix M Mottaghy; Christelle Terwinghe; Kristof Baete; Ivan Borbath; Christophe M Deroose
Significant impact of transient deterioration of renal function on dosimetry in PRRT.
Eric Van Cutsem; Chris Verslype; Karen Soussan-Lazard; Sabine Tejpar; Sylvie Assadourian; Bertrand Billemont; Sylvaine Cartot-Cotton; David Khayat; Jean-Baptiste Meric; Olivier Rixe
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eric Van Cutsem (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Hannah van Malenstein; Jeroen Dekervel; Frederik Nevens; Eric Van Cutsem; Chris Verslype; Petra Windmolders; Jos van Pelt
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Cancer letters 2013;329(1):74-83.
2013: Sofie Van Binnebeek; Eric Van Cutsem; Bert Vanbilloen; Alfons Verbruggen; Chris Verslype; Karin Haustermans; Luc Mortelmans; Felix M Mottaghy; Christelle Terwinghe; Kristof Baete; Ivan Borbath; Christophe M Deroose
Significant impact of transient deterioration of renal function on dosimetry in PRRT.
Annals of nuclear medicine 2013;27(1):74-7.
2013: Eric Van Cutsem; Chris Verslype; Karen Soussan-Lazard; Sabine Tejpar; Sylvie Assadourian; Bertrand Billemont; Sylvaine Cartot-Cotton; David Khayat; Jean-Baptiste Meric; Olivier Rixe
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2013;49(1):17-24.
2012: Aimery de Gramont; J Randolph Hecht; Thierry André; Emilio Bajetta; György Bodoky; Thomas H Cartwright; Stephen Clarke; David Cunningham; Seock-Ah Im; Frédérique Maindrault-Goebel; Martina Makrutzki; Malcolm J Moore; Fernando Rivera; Ramon Salazar; Hans-Joachim Schmoll; Einat Shacham-Shmueli; Aijing Shang; Josep Tabernero; Eric Van Cutsem; Paulo M Hoff
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
The lancet oncology 2012;13(12):1225-33.
2012: D Hompes; Freddy Penninckx; J Tiek; Eric Van Cutsem; A Wolthuis; Steffen Fieuws; Andre D'Hoore
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(12):3123-9.
2012: Sabine Tejpar; Carsten Bokemeyer; Ilhan Celik; Ute Sartorius; Michael Schlichting; Eric Van Cutsem
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(29):3570-7.
2012: Thomas Seufferlein; Eric Van Cutsem; J B Bachet; P Rougier
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 7():vii33-40.
2012: Eric Van Cutsem; Guy Van Hazel; Rémi Castan; David Ferry; Radek Lakomy; Teresa Macarulla; Joe McKendrick; Vladimir Moiseyenko; Jonathan Polikoff; Jana Prausová; Hans Prenen; Paul Ruff; Josep Tabernero; Alexia Tellier; Carmen Allegra
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(28):3499-506.
2012: Albert M Wolthuis; Gert De Hertogh; Steffen Fieuws; Karin Haustermans; Freddy Penninckx; Eric Van Cutsem; Andre D'Hoore
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
Annals of surgical oncology 2012;19(9):2833-41.
2012: Eric Van Cutsem; Dirk Vanbeckevoort; Jan B Vermorken; Frederic Viret; Soetkin Vlassak; Annemieke Cats; Elisa Gallerani; Hans Gelderblom; Bengt Glimelius; Alain Hendlisz; Yves Humblet; Markus Moehler; Marc Peeters; Xavier Sagaert; Michael Schlichting; Sabine Tejpar; Fortunato Ciardiello
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(23):2861-8.
2012: Baki Topal; Eric Van Cutsem; Raymond Aerts; Steffen Fieuws; Tania Roskams; Joyce Tiek; Hans Prenen
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors.
Surgical endoscopy 2012;26(8):2288-98.
2012: Diether Lambrechts; Massimiliano Mazzone; Joke Reumers; Stefan J Scherer; Sabine Tejpar; Peter Carmeliet; Bart Claes; Sanne de Haas; Paul Delmar; Roland Devlieger; Chris Verslype; Hans Wildiers; Betül T Yesilyurt; Eric Van Cutsem
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
The lancet oncology 2012;13(7):724-33.
2012: D Hompes; Claude Bertrand; Wim Ceelen; Andre D'Hoore; Steffen Fieuws; Hugues Legendre; Marc Peeters; Eric Van Cutsem; Kurt Van der Speeten; Joseph Kerger
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Annals of surgical oncology 2012;19(7):2186-94.
2012: Maarten Lambrecht; Freddy Penninckx; Sarah Roels; Eric Van Cutsem; Vincent Vandecaveye; Frederik De Keyzer; Claus Filip; Karin Haustermans
Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
International journal of radiation oncology, biology, physics 2012;82(2):863-70.
2011: Andreia Costa; Hans Prenen; Sabine Tejpar; Eric Van Cutsem
Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.
Targeted oncology 2011;6(4):227-33.
2011: J Cassidy; F Gilberg; P Hoff; Y Kang; J P Saini; Leonard B Saltz; Chris Twelves; Eric Van Cutsem; D Cunningham
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2604-9.
2011: M A Tempero; J Berlin; M Ducreux; D Haller; P Harper; D Khayat; H-J Schmoll; A Sobrero; Eric Van Cutsem
Pancreatic cancer treatment and research: an international expert panel discussion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(7):1500-6.
2011: Eric Van Cutsem; C Van de Velde; N Arber; Y Bang; A Benson; A Cervantes; E Diaz-Rubio; Mario Dicato; M Ducreux; R Geva; R Glynne-Jones; A Grothey; D Haller; Karin Haustermans; Y K Kang; D Kerr; Roberto Labianca; Florian Lordick; J Marshall; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; A Roth; Philippe Rougier; HJ Schmoll; Alberto Sobrero; Josep Tabernero; J Zalcberg
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22 Suppl 5():v1-9.
2011: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; D Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2011-9.
2011: Eric Van Cutsem; Emilio Bajetta; Juan Valle; Claus-Henning Köhne; Malcolm Moore; Colin Germond; William Berg; Bee-Lian Chen; Tarja Jalava; David Lebwohl; Gerold Meinhardt; Dirk Laurent; J Randolph Hecht; Edward Lin
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2004-10.
2011: Herbert I Hurwitz; Leonard B Saltz; Eric Van Cutsem; James Cassidy; Jonas Wiedemann; Florin Sirzén; Gary H Lyman; Ulrich-Peter Rohr
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1757-64.
2011: Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James F Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):934-43.
2011: Albert M Wolthuis; Freddy Penninckx; Karin Haustermans; Nadine Ectors; Eric Van Cutsem; André D'Hoore
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
Annals of surgical oncology 2011;18(3):684-90.
2011: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
The New England journal of medicine 2011;364(6):501-13.
2011: David Miles; Nadia Harbeck; Bernard Escudier; Herbert Hurwitz; Leonard Saltz; Eric Van Cutsem; Jim Cassidy; Barbara Mueller; Florin Sirzén
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(1):83-8.
2010: Ravit Geva; Hans Prenen; Baki Topal; Raymond Aerts; Jaarke Vannoote; Eric Van Cutsem
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.
Journal of surgical oncology 2010;102(8):937-45.
2010: Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; R John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
JAMA : the journal of the American Medical Association 2010;304(16):1812-20.
2010: Maarten Lambrecht; Christophe Deroose; Sarah Roels; Vincent Vandecaveye; Freddy Penninckx; Xavier Sagaert; Eric Van Cutsem; Frederik De Keyzer; Karin Haustermans
The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer.
Acta oncologica (Stockholm, Sweden) 2010;49(7):956-63.
2010: Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem
Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model.
European radiology 2010;20(10):2372-80.
2010: Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet 2010;376(9742):687-97.
2010: Hannah van Malenstein; Olivier Gevaert; Louis Libbrecht; Anneleen Daemen; Joke Allemeersch; Frederik Nevens; Eric Van Cutsem; David Cassiman; Bart De Moor; Chris Verslype; Jos van Pelt
A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(16):4278-88.
2010: Geert Maleux; Johan Vaninbroukx; Sam Heye; Eric Van Cutsem; Raymond Oyen
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Acta oncologica (Stockholm, Sweden) 2010;49(6):864-6.
2010: Eric Van Cutsem; Mario Dicato; N Arber; J Berlin; A Cervantes; Fortunato Ciardiello; A De Gramont; E Diaz-Rubio; M Ducreux; R Geva; Bengt Glimelius; R Glynne Jones; A Grothey; T Gruenberger; D Haller; Karin Haustermans; Roberto Labianca; H J Lenz; B Minsky; Bernard Nordlinger; A Ohtsu; N Pavlidis; Philippe Rougier; W Schmiegel; C Van de Velde; HJ Schmoll; Alberto Sobrero; Josep Tabernero
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 6():vi1-10.
2010: Xavier Sagaert; Eric Van Cutsem; Gert De Hertogh; Karel Geboes; Thomas Tousseyn
Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.
Nature reviews. Gastroenterology & hepatology 2010;7(6):336-46.
2010: Eric Van Cutsem; Bernard Nordlinger; A Cervantes
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 5():v93-7.
2010: Eric Van Cutsem; Fortunato Ciardiello
The search for optimal response prediction in cancer leads to a personalized approach.
Targeted oncology 2010;5(1):3-4.
2010: Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; D Cunningham; Eric Van Cutsem; Fred Bosman
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):466-74.
2010: James C Yao; Catherine Lombard-Bohas; Eric Baudin; Larry K Kvols; Philippe Rougier; Philippe Ruszniewski; Sakina Hoosen; Jessica St Peter; Tomas Haas; David Lebwohl; Eric Van Cutsem; Matthew H Kulke; Timothy J Hobday; Thomas M O'Dorisio; Manisha H Shah; Guillaume Cadiot; Gabriele Luppi; James A Posey; Bertram Wiedenmann
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):69-76.
2009: Annelies Debucquoy; Sarah Roels; Laurence Goethals; Louis Libbrecht; Eric Van Cutsem; Karel Geboes; Freddy Penninckx; André D'Hoore; william mcbride; Karin Haustermans
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;93(2):273-8.
2009: Eric Van Cutsem; F Rivera; S Berry; A Kretzschmar; M Michael; M DiBartolomeo; M-A Mazier; Jean-Luc Canon; V Georgoulias; M Peeters; J Bridgewater; D Cunningham
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(11):1842-7.
2009: Bart Jacobs; Wendy De Roock; Hubert Piessevaux; Robin Van Oirbeek; Bart Biesmans; Joris De Schutter; Steffen Fieuws; Jo Vandesompele; M Peeters; Jean-Luc Van Laethem; Yves Humblet; Frederique Pénault-Llorca; Gert De Hertogh; Pierre Laurent-Puig; Eric Van Cutsem; Sabine Tejpar
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5068-74.
2009: Siegfried Segaert; Gabriela Chiritescu; Liesbeth Lemmens; Kristien Dumon; Eric Van Cutsem; Sabine Tejpar
Skin toxicities of targeted therapies.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():295-308.
2009: Hans Prenen; Sabine Tejpar; Eric Van Cutsem
Impact of molecular markers on treatment selection in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():70-8.
2009: Vincenzo Valentini; Cynthia Aristei; Bengt Glimelius; Bruce D Minsky; Regina G H Beets-Tan; Jose M Borras; Karin Haustermans; Philippe Maingon; Jens Overgaard; Lars Pahlman; Phil Quirke; Hans-Joachim Schmoll; David Sebag-Montefiore; Irving Taylor; Eric Van Cutsem; Cornelius Van de Velde; Numa Cellini; Paolo Latini
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(2):148-63.
2009: Hubert Piessevaux; Marc Buyse; W De Roock; H Prenen; M Schlichting; Eric Van Cutsem; S Tejpar
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1375-82.
2009: Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto Sobrero; Enrico Mini; richard greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; D Cunningham
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3117-25.
2009: Chris Verslype; Eric Van Cutsem; Mario Dicato; N Arber; J D Berlin; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; T Gruenberger; D Haller; Karin Haustermans; P Hoff; D Kerr; R Labianca; M Moore; Bernard Nordlinger; A Ohtsu; Philippe Rougier; W Scheithauer; HJ Schmoll; Alberto Sobrero; Josep Tabernero; C van de Velde
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 7():vii1-vii6.
2009: Eric Van Cutsem; J Oliveira
Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():61-3.
2009: Eric Van Cutsem; J Oliveira
Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():49-50.
2009: Hans Prenen; Joris De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3184-8.
2009: Eric Van Cutsem; Walter L Vervenne; Jaafar Bennouna; Yves Humblet; Sharlene Gill; Jean-Luc Van Laethem; Chris Verslype; Werner Scheithauer; Aijing Shang; Jan Cosaert; Malcolm J Moore
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2231-7.
2009: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
The New England journal of medicine 2009;360(14):1408-17.
2009: Chris Verslype; S Carton; I Borbath; T Delaunoit; P Demetter; G Demolin; Alain Hendlisz; Piet Pattyn; S Pauwels; M Peeters; G Roeyen; Ph Van Hootegem; Jean-Luc Van Laethem; Eric Van Cutsem
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Acta gastro-enterologica Belgica 2009;72(1):54-8.
2009: I Dero; M De Pauw; Ivan Borbath; T Delaunoit; Pieter Demetter; G Demolin; Alain Hendlisz; Piet Pattyn; Stanislas Pauwels; G Roeyen; Eric Van Cutsem; Ph Van Hootegem; Jean-Luc Van Laethem; Chris Verslype; Marc Peeters
Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Acta gastro-enterologica Belgica 2009;72(1):34-8.
2009: Ivan Borbath; F Jamar; T Delaunoit; P Demetter; G Demolin; A Hendlisz; Piet Pattyn; Marc Peeters; G Roeyen; Eric Van Cutsem; Ph Van Hootegem; Jean-Luc Van Laethem; Chris Verslype; Stanislas Pauwels
Diagnostic pitfalls in digestive neuroendocrine tumours.
Acta gastro-enterologica Belgica 2009;72(1):29-33.
2009: Frédéric Di Fiore; Eric Van Cutsem
Acute and long-term gastrointestinal consequences of chemotherapy.
Best practice & research. Clinical gastroenterology 2009;23(1):113-24.
2008: Emmanuel Mitry; Anthony L A Fields; Harry Bleiberg; Roberto Labianca; Guillaume Portier; Dongsheng Tu; Donato Nitti; Valter Torri; Dominique Elias; Chris O'Callaghan; Bernard Langer; Giancarlo Martignoni; Olivier Bouché; Franck Lazorthes; Eric Van Cutsem; Laurent Bedenne; Malcolm J Moore; Philippe Rougier
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4906-11.
2008: Johan Vansteenkiste; Eric Van Cutsem; Herlinde Dumez; Cong Chen; Justin L Ricker; Sophia S Randolph; Patrick Schöffski
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Investigational new drugs 2008;26(5):483-8.
2008: Nicola Personeni; Steffen Fieuws; Hubert Piessevaux; Gert De Hertogh; Joris De Schutter; Bart Biesmans; Wendy De Roock; An Capoen; Maria Debiec-Rychter; Jean-Luc Van Laethem; Marc Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5869-76.
2008: Didier Bielen; Ragna Vanslembrouck; Frederik De Keyzer; Hilde Vandenhout; Lutz Guendel; Eric Van Cutsem; Guy Marchal
Computed tomographic colonography: automated tool for polyp measurement delivering on patient risk stratification.
Journal of computer assisted tomography 2008;32(4):504-10.
2008: Eric Van Cutsem; Mario Dicato; Karin Haustermans; N Arber; J-F Bosset; D Cunningham; A De Gramont; E Diaz-Rubio; M Ducreux; Richard M Goldberg; R Glynne-Jones; D Haller; Y-K Kang; D Kerr; R Labianca; B Minsky; M Moore; Bernard Nordlinger; Philippe Rougier; W Scheithauer; HJ Schmoll; Alberto Sobrero; Josep Tabernero; M Tempero; C Van de Velde; J Zalcberg
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 6():vi1-8.
2008: Jim Cassidy; Hans-Joachim Schmoll; Eric Van Cutsem
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2226-7; author reply 2228.
2008: Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2118-23.
2008: Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1626-34.
2008: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf Bechstein; John Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Lancet 2008;371(9617):1007-16.
2008: Gunnar Folprecht; Matthew T Seymour; Leonard B Saltz; Jean-Yves Douillard; Hartmut Hecker; Richard J Stephens; Timothy S Maughan; Eric Van Cutsem; Philippe Rougier; Emmanuel Mitry; Ute Schubert; Claus-Henning Köhne
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1443-51.
2008: W De Roock; Hubert Piessevaux; Joris De Schutter; M Janssens; Gert De Hertogh; Nicola Personeni; B Biesmans; Jean-Luc Van Laethem; M Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):508-15.
2008: Eric Van Cutsem; Chris Verslype; P Beale; S Clarke; Roland Bugat; Ashok Rakhit; S H Fettner; Ulrich Brennscheidt; Andrea Feyereislova; Jean-Pierre Delord
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):332-9.
2008: Tom Budiharto; Karin Haustermans; Eric Van Cutsem; Werner Van Steenbergen; Baki Topal; Raymond Aerts; Nadine Ectors; Didier Bielen; Dirk Vanbeckevoort; Laurence Goethals; Chris Verslype
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Radiation oncology (London, England) 2008;3():30.
2008: Chris Verslype; Hans Prenen; Eric Van Cutsem
The role of chemotherapy in biliary tract carcinoma.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2008;10(3):164-7.
2008: Bertram Wiedenmann; Peter Malfertheiner; Helmut Friess; Paul Ritch; James Arseneau; Giovanni Mantovani; Francesco Caprioni; Eric Van Cutsem; Dirk Richel; Mark DeWitte; Ming Qi; Don Robinson; Bob Zhong; Carla De Boer; J D Lu; Uma Prabhakar; Robert Corringham; Daniel Von Hoff
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
The journal of supportive oncology 2008;6(1):18-25.
2008: Eric Van Cutsem; Cornelius Van de Velde; A Roth; Florian Lordick; Claus-Henning Köhne; Stefano Cascinu; Matti Aapro
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
European journal of cancer (Oxford, England : 1990) 2008;44(2):182-94.
2008: Eric Van Cutsem; Salvatore Siena; Yves Humblet; Jean-Luc Canon; J Maurel; Emilio Bajetta; Bart Neyns; Dusan Kotasek; A Santoro; W Scheithauer; S Spadafora; Rafael G Amado; N Hogan; M Peeters
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):92-8.
2007: S Siena; M Peeters; Eric Van Cutsem; Yves Humblet; P Conte; Emilio Bajetta; D Comandini; György Bodoky; G Van Hazel; T Salek; M Wolf; G Devercelli; M Woolley; Rafael G Amado
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
British journal of cancer 2007;97(11):1469-74.
2007: Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5225-32.
2007: Hans G Smeenk; C H J van Eijck; Wim C Hop; Joris Erdmann; Kheetje C K Tran; Muriel Debois; Eric Van Cutsem; Herman van Dekken; J H G Klinkenbijl; Johannes Jeekel
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.
Annals of surgery 2007;246(5):734-40.
2007: Siegfried Segaert; Eric Van Cutsem
Clinical management of EGFRI dermatologic toxicities: the European perspective.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):22-6.
2007: Roman Perez-Soler; Eric Van Cutsem
Clinical research of EGFR inhibitors and related dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):10-6.
2007: Edith P Mitchell; Roman Perez-Soler; Eric Van Cutsem; Mario Lacouture
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):4-9.
2007: Eric Van Cutsem
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer.
Clinical colorectal cancer 2007;6 Suppl 2():S60-5.
2007: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; FELICE GIULIANTE; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2037-45.
2007: Pernilla Lagergren; Peter M Fayers; Thierry Conroy; Hubert J Stein; Orhan Sezer; Richard Hardwick; Eva Hammerlid; andrew bottomley; Eric Van Cutsem; Jane M Blazeby
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2066-73.
2007: Eric Van Cutsem
Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer.
Clinical advances in hematology & oncology : H&O 2007;5(8):611-3.
2007: Wouter M Tiel Groenestege; Stéphanie Thébault; Jenny van der Wijst; Dennis van den Berg; Rob Janssen; Sabine Tejpar; Lambert P van den Heuvel; Eric Van Cutsem; Joost G J Hoenderop; Nine V A M Knoers; René J M Bindels
Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.
The Journal of clinical investigation 2007;117(8):2260-7.
2007: Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Lucile Awad; Eric Van Cutsem
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3210-6.
2007: Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Cindy Marabotti; Eric Van Cutsem
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3205-9.
2007: Manfred P Lutz; Hansjochen Wilke; D J Th Wagener; Udo Vanhoefer; Krzysztof Jeziorski; Susanna Hegewisch-Becker; Leopold Balleisen; Eric Joossens; Rob L Jansen; Muriel Debois; Ullrich Bethe; Michel Praet; Jacques A Wils; Eric Van Cutsem
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2580-5.
2007: Chris Verslype; Eric Van Cutsem; Mario Dicato; S Cascinu; D Cunningham; E Diaz-Rubio; Bengt Glimelius; D Haller; Karin Haustermans; V Heinemann; P Hoff; P G Johnston; D Kerr; R Labianca; C Louvet; B Minsky; M Moore; Bernard Nordlinger; S Pedrazzoli; A Roth; M Rothenberg; Philippe Rougier; HJ Schmoll; Josep Tabernero; M Tempero; C van de Velde; Jean-Luc Van Laethem; J Zalcberg
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 7():vii1-vii10.
2007: Nadia Farroni; Anita Van den Bosch; Karin Haustermans; Eric Van Cutsem; Philip Moons; Andre D'Hoore; Freddy Penninckx
Perineal colostomy with appendicostomy as an alternative for an abdominal colostomy: symptoms, functional status, quality of life, and perceived health.
Diseases of the colon and rectum 2007;50(6):817-24.
2007: Eric Van Cutsem; Chris Verslype; Patrick A Grusenmeyer
Lessons learned in the management of advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):1949-52.
2007: Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1658-64.
2007: Sabine Tejpar; Hubert Piessevaux; Kathleen Claes; Patricia Piront; Joost G J Hoenderop; Chris Verslype; Eric Van Cutsem
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
The lancet oncology 2007;8(5):387-94.
2007: Jean-Pascal Machiels; Christine Sempoux; Pierre Scalliet; J-C Coche; Yves Humblet; Eric Van Cutsem; Joseph Kerger; Jean-Luc Canon; M Peeters; S Aydin; S Laurent; Alex Kartheuser; B Coster; Sarah Roels; J-F Daisne; B Honhon; Lionel DUCK; C Kirkove; M-A Bonny; Karin Haustermans
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):738-44.
2007: Eric Van Cutsem; Karel Geboes
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Best practice & research. Clinical gastroenterology 2007;21(6):1089-108.
2007: Heiko Fensterer; Bernhard Radlwimmer; Jörn Sträter; Malte Buchholz; Daniela E Aust; Catherine Julié; François Radvanyi; Bernard Nordlinger; Claudio Belluco; Eric Van Cutsem; Claus-Henning Köhne; Hans A Kestler; Carsten Schwaenen; Michelle Nessling; Manfred P Lutz; Peter Lichter; Thomas M Gress
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.
BMC cancer 2007;7():58.
2007: Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
The oncologist 2007;12(1):38-50.
2007: Hans-Joachim Schmoll; Thomas Cartwright; Josep Tabernero; Marek P Nowacki; Arie Figer; Jean Maroun; Timothy Price; Robert Lim; Eric Van Cutsem; Young-Suk Park; Joseph McKendrick; Claire Topham; Gemma Soler-Gonzalez; Filipo de Braud; Mark Hill; Florin Sirzén; Daniel G Haller
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):102-9.
2006: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(31):4991-7.
2006: Heinz-Josef Lenz; Eric Van Cutsem; Shirin Khambata-Ford; Robert J Mayer; Philip Gold; Philip Stella; Barry Mirtsching; Allen L Cohn; Andrew W Pippas; Nozar Azarnia; Zenta Tsuchihashi; David J Mauro; Eric K Rowinsky
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4914-21.
2006: Karel Goddeeris; Chris Verslype; Guido Wilms; Eric Van Cutsem
Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature.
Acta gastro-enterologica Belgica 2006;69(4):377-80.
2006: Eric Van Cutsem
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
The oncologist 2006;11(9):1010-7.
2006: Federico Rojo; Josep Tabernero; Joan Albanell; Eric Van Cutsem; Atsushi Ohtsu; Toshihiko Doi; Wasaburo Koizumi; Kuniaki Shirao; Hiroya Takiuchi; Santiago Ramon Y Cajal; S Ramon Cajal; José Baselga
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4309-16.
2006: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2212-21.
2006: Eric Van Cutsem
Progress with biological agents in metastatic colorectal cancer leads to many challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3325-7.
2006: Eric Van Cutsem; Mario Dicato; N Arber; A Benson; D Cunningham; E Diaz-Rubio; Bengt Glimelius; Richard M Goldberg; D Haller; Karin Haustermans; Y Koo-Kang; R Labianca; I Lang; B Minsky; Bernard Nordlinger; A Roth; Philippe Rougier; HJ Schmoll; Alberto Sobrero; Josep Tabernero; A Szawlowski; C van de Velde
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 6():vi13-8.
2006: Sandra Van Schaeybroeck; Joan Kyula; Donal M Kelly; Anthi Karaiskou-McCaul; Susan A Stokesberry; Eric Van Cutsem; Daniel B Longley; Patrick G Johnston
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Molecular cancer therapeutics 2006;5(5):1154-65.
2006: M Spaepen; B Vankeirsbilck; S Van Opstal; Sabine Tejpar; Eric Van Cutsem; K Geboes; Eric Legius; Gert Matthijs
Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients.
Familial cancer 2006;5(2):179-89.
2006: Fabio Efficace; andrew bottomley; Corneel Coens; Kristel van Steen; Thierry Conroy; Patrick Schöffski; Hans Schmoll; Eric Van Cutsem; Claus-Henning Köhne
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
European journal of cancer (Oxford, England : 1990) 2006;42(1):42-9.
2005: Manfred P Lutz; Eric Van Cutsem; Theo Wagener; Jean-Luc Van Laethem; Udo Vanhoefer; Jacques A Wils; Erick Gamelin; Claus H Koehne; Jean P Arnaud; Emmanuel Mitry; Faress Husseini; Peter Reichardt; Mustafa El-Serafi; Pierre-Luc Etienne; Thomas Lingenfelser; Michel Praet; Bruno Genicot; Muriel Debois; Bernard Nordlinger; Michel P Ducreux
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9250-6.
2005: Eric Van Cutsem; Frederico Costa
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
JAMA : the journal of the American Medical Association 2005;294(21):2758-60.
2005: Laurence Goethals; Karin Haustermans; Christiaan Perneel; barbara bussels; Andre D'Hoore; Karel Geboes; Nadine Ectors; Eric Van Cutsem; Walter Van den Bogaert; Freddy Penninckx
Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):969-76.
2005: Sandra Van Schaeybroeck; Anthi Karaiskou-McCaul; Donal Kelly; Daniel B Longley; Leeona Galligan; Eric Van Cutsem; Patrick Johnston
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7480-9.
2005: Vincenzo Valentini; Bengt Glimelius; Bruce D Minsky; Eric Van Cutsem; Hanry Bartelink; Regina G H Beets-Tan; Jean-Pierre Gerard; Paris Kosmidis; Lars Pahlman; Aurelio Picciocchi; Phil Quirke; Joel E Tepper; Maurizio Tonato; Cornelius J Van de Velde; Numa Cellini; Paolo Latini
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(3):241-50.
2005: Siegfried Segaert; Eric Van Cutsem
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(9):1425-33.
2005: Jaffer A Ajani; Miguel Fodor; Sergei Tjulandin; Vladimir M Moiseyenko; Yee Chao; Sebastiao Cabral Filho; Alejandro Majlis; Sylvie Assadourian; Eric Van Cutsem
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5660-7.
2005: Siegfried Segaert; Josep Tabernero; Olivier Chosidow; Thomas Dirschka; Joern Elsner; Luca Mancini; Tim Maughan; Jean-Fran Ois Morere; Armando Santoro; Alberto Sobrero; Eric Van Cutsem; Alison Layton
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2005;3(8):599-606.
2005: Claus-Henning Köhne; Eric Van Cutsem; Jacques A Wils; Carsten Bokemeyer; Mustafa El-Serafi; Manfred P Lutz; M Lorenz; Peter Reichardt; H Rückle-Lanz; N Frickhofen; R Fuchs; H-G Mergenthaler; T Langenbuch; Udo Vanhoefer; Philippe Rougier; R Voigtmann; L Müller; Bruno Genicot; O Anak; Bernard Nordlinger
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4856-65.
2005: Chris J Twelves; Charles A Butts; Jim Cassidy; Thierry Conroy; Fillippo de Braud; Eduardo Diaz-Rubio; Josep Tabernero; Patrick Schoffski; Arie Figer; Rene Brunet; Johannes Grossmann; Alberto Sobrero; Eric Van Cutsem
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Clinical colorectal cancer 2005;5(2):101-7.
2005: Bernard Nordlinger; Philippe Rougier; Jean-Pierre Arnaud; Muriel Debois; Jacques A Wils; Jean-Claude Ollier; Olivier Grobost; Philippe Lasser; Jacob Wals; Jerome Lacourt; Jean-François Seitz; Jose Guimares dos Santos; Harry Bleiberg; Rémy Mackiewickz; Thierry Conroy; Olivier Bouché; Thierry Morin; Liliana Baila; Eric Van Cutsem; Laurent Bedenne
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
The lancet oncology 2005;6(7):459-68.
2005: Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Gastric cancer.
Critical reviews in oncology/hematology 2005;54(3):209-41.
2005: Eric Van Cutsem; L Dirix; Jean-Luc Van Laethem; Simon Van Belle; Markus M Borner; M Gonzalez Baron; A Roth; Rudolf Morant; E Joosens; G Gruia; D Sibaud; Harry Bleiberg
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
British journal of cancer 2005;92(6):1055-62.
2005: Eric Van Cutsem; Chris Verslype; Sabine Tejpar
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Seminars in oncology 2005;32(1):43-51.
2005: Michel Ducreux; Eric Van Cutsem; J L Van Laethem; T M Gress; Krzysztof Jeziorski; Philippe Rougier; T Wagener; O Anak; Benoît Baron; Bernard Nordlinger
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
European journal of cancer (Oxford, England : 1990) 2005;41(3):398-403.
2005: Geneviève Michils; Sabine Tejpar; Reinhilde Thoelen; Eric Van Cutsem; Joris R Vermeesch; Jean-Pierre Fryns; Eric Legius; Gert Matthijs
Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study.
Human mutation 2005;25(2):125-34.
2005: Eric Van Cutsem; Jann Arends
The causes and consequences of cancer-associated malnutrition.
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2005;9 Suppl 2():S51-63.
2005: Aimery de Gramont; Eric Van Cutsem
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
Oncology 2005;69 Suppl 3():46-56.
2004: Eric Van Cutsem
Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?
Nature clinical practice. Gastroenterology & hepatology 2004;1(2):72-3.
2004: Olga Vrieze; Karin Haustermans; Walter De Wever; Toni Lerut; Eric Van Cutsem; Nadine Ectors; Martin Hiele; Patrick Flamen
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;73(3):269-75.
2004: Jane M Blazeby; Thierry Conroy; andrew bottomley; Craig W Vickery; Juan Ignacio Arraras; Orhan Sezer; J Moore; M Koller; N S Turhal; R Stuart; Eric Van Cutsem; Sven D'haese; Corneel Coens
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2260-8.
2004: Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya L Charette; Daniel G Haller
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3408-19.
2004: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine 2004;351(4):337-45.
2004: Jim Cassidy; Josep Tabernero; Chris Twelves; René Brunet; Charles Butts; Thierry Conroy; Filippo Debraud; Arie Figer; Johannes Grossmann; Noriaki Sawada; Patrick Schöffski; Alberto Sobrero; Eric Van Cutsem; Eduardo Díaz-Rubio
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2084-91.
2004: Eric Van Cutsem; H van de Velde; P Karasek; Helmut Oettle; W L Vervenne; A Szawlowski; Patrick Schoffski; S Post; Chris Verslype; H Neumann; H Safran; Yves Humblet; Juan Jose Perez-Ruixo; Y Ma; Daniel Von Hoff
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1430-8.
2004: Eric Van Cutsem; P M Hoff; P Harper; R M Bukowski; D Cunningham; P Dufour; U Graeven; J Lokich; S Madajewicz; Jean Maroun; J L Marshall; E P Mitchell; G Perez-Manga; Philippe Rougier; W Schmiegel; J Schoelmerich; Alberto Sobrero; R L Schilsky
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
British journal of cancer 2004;90(6):1190-7.
2004: Eric Van Cutsem; Raymond Aerts; Karin Haustermans; Baki Topal; Werner Van Steenbergen; Chris Verslype
Systemic treatment of pancreatic cancer.
European journal of gastroenterology & hepatology 2004;16(3):265-74.
2004: Philippe Ruszniewski; Sophia Ish-Shalom; Machteld Wymenga; Dermot O'Toole; Rudolf Arnold; Paola Tomassetti; Nigel Bax; Martyn E Caplin; Barbro Eriksson; Benjamin Glaser; Michel Ducreux; Catherine Lombard-Bohas; Wouter W de Herder; Gianfranco Delle Fave; Nick Reed; Jean François Seitz; Eric Van Cutsem; Ashley Grossman; Philippe Rougier; Wolfgang Schmidt; Bertram Wiedenmann
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Neuroendocrinology 2004;80(4):244-51.
2004: Hilde Marsé; Eric Van Cutsem; Axel Grothey; Sonia Valverde
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2004;8 Suppl 1():S16-30.
2004: Eric Van Cutsem
The treatment of advanced gastric cancer: new findings on the activity of the taxanes.
The oncologist 2004;9 Suppl 2():9-15.
2003: Maarten Thomeer; Iacopo Carbone; Hilde Bosmans; Gabriel Kiss; Didier Bielen; Dirk Vanbeckevoort; Eric Van Cutsem; Paul Rutgeerts; Guy Marchal
Stool tagging applied in thin-slice multidetector computed tomography colonography.
Journal of computer assisted tomography 2003;27(2):132-9.
2003: Sabine Tejpar; Eric Van Cutsem
Molecular defects in colorectal tumorigenesis.
Drugs of today (Barcelona, Spain : 1998) 2003;39 Suppl C():111-8.
2003: J-Y Douillard; Alberto Sobrero; Carlo Carnaghi; P Comella; Eduardo Díaz-Rubio; A Santoro; Eric Van Cutsem
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 2():ii7-12.
2002: Geneviève Michils; Sabine Tejpar; Jean-Pierre Fryns; Eric Legius; Eric Van Cutsem; Jean-Jacques Cassiman; Gert Matthijs
Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD).
European journal of human genetics : EJHG 2002;10(9):505-10.
2002: Eric Van Cutsem; Mario Dicato; Jacques A Wils; D Cunningham; E Diaz-Rubio; Bengt Glimelius; D Haller; P Johnston; D Kerr; C H Koehne; R Labianca; B Minsky; Bernard Nordlinger; A Roth; Philippe Rougier; HJ Schmoll
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
European journal of cancer (Oxford, England : 1990) 2002;38(11):1429-36.
2002: Maarten Thomeer; Didier Bielen; Dirk Vanbeckevoort; Steven Dymarkowski; Anna-Maria Gevers; Paul Rutgeerts; M Hiele; Eric Van Cutsem; Guy Marchal
Patient acceptance for CT colonography: what is the real issue?
European radiology 2002;12(6):1410-5.
2002: Thierry Conroy; Pierre-Luc Etienne; Antoine Adenis; Michel Ducreux; Bernard Paillot; J Oliveira; Jean-François Seitz; Eric Francois; Eric Van Cutsem; D J Th Wagener; F Kohser; S Daamen; M Praet; Thierry Gorlia; Benoît Baron; Jacques A Wils
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):721-9.
2002: Jim Cassidy; Chris Twelves; Eric Van Cutsem; P Hoff; Emilio Bajetta; Michael Boyer; R Bugat; U Burger; A Garin; U Graeven; J McKendric; Jean Maroun; J Marshall; B Osterwalder; G Pérez-Manga; R Rosso; Philippe Rougier; R L Schilsky
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):566-75.
2002: Eric Van Cutsem; D Cunningham; Jean Maroun; A Cervantes; Bengt Glimelius
Raltitrexed: current clinical status and future directions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):513-22.
2002: Eric Van Cutsem; Chris Verslype; Ingrid Demedts
The treatment of advanced colorectal cancer: where are we now and where do we go?
Best practice & research. Clinical gastroenterology 2002;16(2):319-30.
2002: Sabine Tejpar; Eric Van Cutsem
Molecular and genetic defects in colorectal tumorigenesis.
Best practice & research. Clinical gastroenterology 2002;16(2):171-85.
2002: T De Potter; Patrick Flamen; Eric Van Cutsem; Freddy Penninckx; Ludo Filez; Guy Bormans; Alex Maes; Luc Mortelmans
Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
European journal of nuclear medicine and molecular imaging 2002;29(4):525-9.
2002: Eric Van Cutsem; P M Hoff; JL Blum; M Abt; B Osterwalder
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):484-5.
2002: Patrick Flamen; Eric Van Cutsem; Antoon Lerut; J P Cambier; Karin Haustermans; Guy Bormans; Paul De Leyn; Dirk E M Van Raemdonck; Walter De Wever; Nadine Ectors; A Maes; Luc Mortelmans
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):361-8.
2002: O Anak; Eric Van Cutsem; Bernard Nordlinger
The EORTC Gastrointestinal Tract Cancer Group: 40 years of research contributing to improved GI cancer management.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S65-70.
2002: Eric Van Cutsem; Daniel Haller; Atsushi Ohtsu
The role of chemotherapy in the current treatment of gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2002;5 Suppl 1():17-22.
2002: Thomas L Abell; Eric Van Cutsem; Hasse Abrahamsson; Jan D Huizinga; J W Konturek; Jean-Paul Galmiche; Guy VoelIer; Ludo Filez; Bernt Everts; William E Waterfall; W Domschke; Stanislas Bruley des Varannes; Babajide O Familoni; Ivan M Bourgeois; Jozef Janssens; Gervais Tougas
Gastric electrical stimulation in intractable symptomatic gastroparesis.
Digestion 2002;66(4):204-12.
2001: Eric Van Cutsem; Mario Dicato; Jacques A Wils
Recent advances in the management of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2302-9.
2001: Eric Van Cutsem; Chris Twelves; Jim Cassidy; D Allman; Emilio Bajetta; Michael Boyer; R Bugat; Michael Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; Philippe Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4097-106.
2001: Sabine Tejpar; C Li; C Yu; Raymond Poon; Hannelore Denys; Raf Sciot; Eric Van Cutsem; Jean-Jacques Cassiman; Benjamin A Alman
Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour).
British journal of cancer 2001;85(1):98-101.
2001: Sabine Tejpar; Jean-Jacques Cassiman; Eric Van Cutsem
The molecular basis of colorectal cancer.
Acta gastro-enterologica Belgica 2001;64(3):249-54.
2001: Patrick Flamen; O S Hoekstra; F Homans; Eric Van Cutsem; A Maes; Sigrid Stroobants; M Peeters; Freddy Penninckx; Ludo Filez; R P Bleichrodt; L Mortelmans
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
European journal of cancer (Oxford, England : 1990) 2001;37(7):862-9.
2001: Baki Topal; Patrick Flamen; Raymond Aerts; Andre D'Hoore; Ludo Filez; Eric Van Cutsem; Luc Mortelmans; Freddy Penninckx
Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(2):175-9.
2001: Eric Van Cutsem; D Cunningham; P M Hoff; Jean Maroun
Thymidine phosphorylase (TP) activation: convenience through innovation.
The oncologist 2001;6 Suppl 4():1-2.
2000: Toni Lerut; Patrick Flamen; Nadine Ectors; Eric Van Cutsem; M Peeters; Martin Hiele; Walter De Wever; Willy Coosemans; Georges Decker; Paul De Leyn; Georges Deneffe; Dirk E M Van Raemdonck; Luc Mortelmans
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.
Annals of surgery 2000;232(6):743-52.
2000: Patrick Flamen; Antoon Lerut; Eric Van Cutsem; J P Cambier; A Maes; Walter De Wever; M Peeters; Paul De Leyn; Dirk E M Van Raemdonck; L Mortelmans
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
The Journal of thoracic and cardiovascular surgery 2000;120(6):1085-92.
2000: Eric Van Cutsem; M Peeters
Oral fluoropyrimidines in colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):91-5.
2000: Patrick Flamen; Eric Van Cutsem; Luc Mortelmans
A new imaging technique for colorectal cancer: positron emission tomography.
Seminars in oncology 2000;27(5 Suppl 10):22-9.
2000: Patrick Flamen; Antoon Lerut; Eric Van Cutsem; Walter De Wever; M Peeters; Sigrid Stroobants; Patrick Dupont; Guy Bormans; Martin Hiele; Paul De Leyn; Dirk E M Van Raemdonck; Willy Coosemans; Nadine Ectors; Karin Haustermans; Luc Mortelmans
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3202-10.
2000: Eric Van Cutsem; Michael Findlay; B Osterwalder; Walter Kocha; D Dalley; R Pazdur; Jim Cassidy; L Dirix; Chris Twelves; D Allman; J F Seitz; J Schölmerich; Hans-Ulrich Burger; Jaap Verweij
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1337-45.
2000: Eric Van Cutsem; Karin Haustermans; Werner Van Steenbergen
New treatment possibilities for pancreatic and biliary tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():165-9.
1999: Sabine Tejpar; Friedel Nollet; C Li; J S Wunder; Geneviève Michils; P dal Cin; Eric Van Cutsem; Bharati Bapat; Frans van Roy; Jean-Jacques Cassiman; Benjamin A Alman
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).
Oncogene 1999;18(47):6615-20.
1999: Jean-Pierre Armand; D Cunningham; Eric Van Cutsem; Jean-Louis Misset; C H Kohne
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Anti-cancer drugs 1999;10 Suppl 1():S5-12.
1999: A Driessen; Nadine Ectors; Eric Van Cutsem; Freddy Penninckx; Ludo Filez; S Pittaluga; Jan Delabie; Christiane De Wolf-Peeters; Karel Geboes
Different gastritis features are linked to different gastric neoplasms.
Gastroentérologie clinique et biologique 1999;23(6-7):747-53.
1999: Eric Van Cutsem
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
European journal of cancer (Oxford, England : 1990) 1999;35 Suppl 1():S1-2.
1999: Eric Van Cutsem; M Peeters; Chris Verslype; Ludo Filez; Karin Haustermans; J Janssens
The medical treatment of colorectal cancer: actual status and new developments.
Hepato-gastroenterology 1999;46(26):709-16.
1999: Ludo Filez; Freddy Penninckx; Nadine Ectors; Eric Van Cutsem; Karel Geboes; Raymond Aerts; Andre D'Hoore; R Kerremans
Radioimmunoguided surgery for colorectal carcinoma.
Hepato-gastroenterology 1999;46(26):691-700.
1999: Karin Haustermans; J Fowler; Karel Geboes; Antoon Lerut; Eric Van Cutsem; Adrian C Begg
Cell kinetic measurements: principles, guidelines for treatment?
Hepato-gastroenterology 1999;46(26):670-8.
1999: Patrick Flamen; Sigrid Stroobants; Eric Van Cutsem; Patrick Dupont; Guy Bormans; N De Vadder; Freddy Penninckx; L Van Hoe; Luc Mortelmans
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):894-901.
1999: Eric Van Cutsem; Geert H Blijham
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Seminars in oncology 1999;26(1 Suppl 5):13-20.
1999: Luc Stockx; H Raat; B Caerts; Eric Van Cutsem; Guido Wilms; Guy Marchal
Transcatheter embolization of hepatic arteriovenous fistulas in Rendu-Osler-Weber disease: a case report and review of the literature.
European radiology 1999;9(7):1434-7.
1999: Eric Van Cutsem; D Cunningham; W W Ten Bokkel Huinink; C J Punt; C G Alexopoulos; L Dirix; M Symann; Geert H Blijham; P Cholet; G Fillet; C Van Groeningen; J M Vannetzel; F Levi; G Panagos; C Unger; Jacques A Wils; C Cote; C Blanc; P Hérait; Harry Bleiberg
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
European journal of cancer (Oxford, England : 1990) 1999;35(1):54-9.
1998: Eric Van Cutsem; Carmelo Pozzo; H Starkhammar; L Dirix; Edmondo Terzoli; F Cognetti; Yves Humblet; Carlo Garufi; Ludo Filez; G Gruia; C Cote; Carlo Barone
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(11):1199-204.
1998: A Driessen; Nadine Ectors; John W M Creemers; Ludo Filez; Freddy Penninckx; Eric Van Cutsem; Karel Geboes
Intestinal metaplasia in gastric malignancy: a comparison between carcinoma and lymphoma.
European journal of gastroenterology & hepatology 1998;10(7):595-600.
1998: Alexander Wilmer; Eric Van Cutsem; A Andrioli; Jan Tack; Georges Coremans; Jozef Janssens
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying.
Gut 1998;42(2):235-42.
1998: Eric De Goede; Ludo Filez; J Janssens; Eric Van Cutsem
Follow-up of colon cancer: detection of liver metastases: benefit and periodicity.
Acta gastro-enterologica Belgica 1998;61(1):8-10.
1997: P Lissens; Ludo Filez; Raymond Aerts; Andre D'Hoore; Eric Van Cutsem; Nadine Ectors; Freddy Penninckx; R Kerremans
Surgery for gastric remnant carcinoma following Billroth II gastrectomy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1997;23(6):518-21.
1997: Eric Van Cutsem
Future developments with 'Tomudex' (raltitrexed).
Anti-cancer drugs 1997;8 Suppl 2():S33-8.
1996: Eric Van Cutsem; H Piessevaux
Pharmacologic therapy of arteriovenous malformations.
Gastrointestinal endoscopy clinics of North America 1996;6(4):819-32.
1996: Eric Van Cutsem
A glimpse of the future. new directions in the treatment of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 5():S23-7.
1995: Eric Van Cutsem; S Tejpar; Paul Rutgeerts; Jozef Janssens
Screening for colorectal cancer.
Acta gastro-enterologica Belgica 1995;58(5-6):397-404.
1995: Eric Van Cutsem; J Fevery
Pancreatic cancer: a plea for more trials.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):867-9.
1995: Eric Van Cutsem; Ludo Filez; J Dewyspelaere; Freddy Penninckx; Jozef Janssens
Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.
Anticancer research 1995;15(3):1079-80.
1993: Eric Van Cutsem; Freddy Penninckx; Ludo Filez; R Kerremans; G Vantrappen
Repeated hepatic ischemia in combination with chemotherapy for liver carcinoid metastases.
Acta gastro-enterologica Belgica 1993;56(3-4):292-5.
1993: Eric Van Cutsem
Georges Brohee Prize. Oestrogen-progesterone, a new therapy of bleeding gastrointestinal vascular malformations.
Acta gastro-enterologica Belgica 1993;56(1):2-10.
1992: V Annese; Jozef Janssens; G Vantrappen; Jan Tack; Theo L Peeters; P Willemse; Eric Van Cutsem
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination.
Gastroenterology 1992;102(3):823-8.
1992: Theo L Peeters; Erik Muls; Jozef Janssens; JL Urbain; Marie Bex; Eric Van Cutsem; Inge Depoortere; MJ de Roo; G Vantrappen; Roger Bouillon
Effect of motilin on gastric emptying in patients with diabetic gastroparesis.
Gastroenterology 1992;102(1):97-101.
1990: JL Urbain; Eric Van Cutsem; Jeffry A Siegel; S Mayeur; A Vandecruys; Jozef Janssens; MJ de Roo; G Vantrappen
Visualization and characterization of gastric contractions using a radionuclide technique.
The American journal of physiology 1990;259(6 Pt 1):G1062-7.
1990: JL Urbain; Freddy Penninckx; Jeffry A Siegel; P Vandenborre; Eric Van Cutsem; V Vandenmaegdenbergh; MJ de Roo
Effect of proximal vagotomy and Roux-en-Y diversion on gastric emptying kinetics in asymptomatic patients.
Clinical nuclear medicine 1990;15(10):688-91.
1990: JL Urbain; G Vantrappen; Jozef Janssens; Eric Van Cutsem; Theo L Peeters; MJ de Roo
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(9):1490-3.
1990: Eric Van Cutsem; Paul Rutgeerts; G Vantrappen
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.
Lancet 1990;335(8695):953-5.
1989: JL Urbain; Jeffry A Siegel; Luc Mortelmans; Eric Van Cutsem; V Van den Maegdenbergh; MJ de Roo
Effect of solid-meal caloric content on gastric emptying kinetics of solids and liquids.
Nuklearmedizin. Nuclear medicine 1989;28(4):120-3.
1988: Eric Van Cutsem; Paul Rutgeerts; Karel Geboes; F Van Gompel; G Vantrappen
Estrogen-progesterone treatment of Osler-Weber-Rendu disease.
Journal of clinical gastroenterology 1988;10(6):676-9.